SCHEMBL26258794

SCHEMBL26258794

CC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OCCC(=O)O)ccc2-n2c(C)nnc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 0.73
SMCHD1 A6NHR9 1/20 0.63
MYO1G B0I1T2 1/20 0.63
AIP O00170 1/20 0.63
AP3B1 O00203 1/20 0.63
PSMD11 O00231 1/20 0.63
CDC7 O00311 1/20 0.63
SAP18 O00422 1/20 0.63
KPNA3 O00505 1/20 0.63
PPP6C O00743 1/20 0.63
TCERG1 O14776 1/20 0.63
UBE2L6 O14933 1/20 0.63
PPP1R12A O14974 1/20 0.63
U2SURP O15042 1/20 0.63
SETD1A O15047 1/20 0.63
ARPC1B O15143 1/20 0.63
POLR1C O15160 1/20 0.63
OGT O15294 1/20 0.63
PPM1G O15355 1/20 0.63
SLC16A3 O15427 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26315854 0.95 BRD4 (0.71) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL26258789 0.91 BRD4 (0.74) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL26258770 0.91 BRD4 (0.69) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL26258843 0.90 BRD4 (0.68) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL14757355 0.90 BRD4 (0.80) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL26258853 0.89 BRD4 (0.66) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL19556889 0.88 BRD4 (0.86) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL15980801 0.88 BRD4 (0.86) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL26258811 0.88 BRD4 (0.65) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL26315928 0.88 BRD4 (0.65) BRD4SMCHD1MYO1GAIPAP3B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM XIAP, CUL4A, CUL1 BRD4 331/4885SMCHD1 1926/4885MYO1G 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.